- Could You Spot the Silent Symptoms of Stress?
- Gas Stoves Could Leave Your Lungs Vulnerable to Nitrogen Dioxide
- Key Therapy Equally Effective for Women, Men With Narrowed Leg Arteries
- Doctors Describe Texas Dairy Farm Worker’s Case of Bird Flu
- Does Preschool Boost Kids’ Long-Term Academic Success? Study Finds Mixed Results
- AI Might Spot Rare Diseases in Patients Years Earlier
- An Orangutan Healed Himself With Medicinal Plant
- Quit-Smoking Meds Not Working for You? Try Upping the Dose
- Fewer Americans Are Suffering Most Dangerous Form of Heart Attack
- Even Skipping Meat for One Meal Helps Liver Disease Patients
First Newborn Screening Test Approved for Rare Immune Disorder
The first test to screen for Severe Combined Immunodeficiency (SCID) in newborns has been approved by the U.S. Food and Drug Administration.
Some 40 to 100 cases of SCID are identified each year among newborns in the United States, the federal Centers for Disease Control and Prevention says. The group of disorders is caused by genetic defects that influence infection-fighting immune cells. While babies with SCID appear normal at birth, they typically develop deadly infections within a few months, the FDA said in a news release. Death commonly occurs during the infant’s first year without early detection and treatment.
The EnLite Neonatal TREC Kit uses a few drops of blood from the baby’s heel to look for traits that can help identify SCID. The FDA said it recommends that all states screen newborns for SCID, among other genetic, endocrine and metabolic disorders.
In clinical testing involving 6,400 newborn-blood samples, the new test correctly identified all 17 samples from newborns confirmed to have SCID, the FDA said.
The new test should not be used to screen for other SCID-like syndromes, the FDA said.
The test is produced by a Finnish subsidiary of PerkinElmer, based in Waltham, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.